Why the study?
Xinmailong injection is widely used to treat heart failure in China, but a meta-analysis was needed to assess its efficacy and safety for improving cardiac function.
Does Xinmailong injection added to conventional treatment improve LVEF, 6MWT, and BNP in patients with heart failure?
Does Xinmailong injection added to conventional treatment improve LVEF, 6MWT, and BNP in patients with heart failure?
Xinmailong injection added to conventional therapy may improve surrogate markers of cardiac function and exercise capacity in heart failure, though current evidence is limited by study heterogeneity and bias.
Answers are grounded in this paper and cite their sources.
Adjunctive XML may enhance cardiac function in HF; extends meta-analytic support for adjunctive use but warrants larger confirmatory trials.
Background . Insect drugs have great potential for treating cardiovascular diseases. Xinmailong (XML) injection, a bioactive composite extracted from Periplaneta americana (a species of cockroach), was wildly used in treating heart failure in China. This meta‐analysis aimed to assess the efficacy and safety of XML injection for the improvement of cardiac function in HF. Materials and Methods . Online literature search for relevant studies was performed using databases including PubMed, EMBASE, Cochrane Library, CNKI, and Wanfang. Left ventricular ejection fraction (LVEF), six‐minute walk test (6MWT), and brain natriuretic peptide (BNP) were selected as target outcomes. The analysis was performed using Stata 12.0, and sources of heterogeneity were explored by subgroup analysis and metaregression. Results . 32 studies were included in this meta‐analysis after meeting the inclusion/exclusion criteria. The results demonstrated that additional use of XML improved LVEF (WMD = 5.82, 95% CI: 5.52–7.13, P < 0.00001) and 6MWT (WMD = 51.48, 95% CI: 35.83–67.13, P < 0.00001) and reduced BNP (WMD = −172.84, 95% CI: −205.79 to −139.89, P < 0.00001). The results of subgroup analyses and metaregression suggested that XML injection has more cardiac function improvement for middle‐aged HF patients than youth, and greater LVEF and 6MWT improvement were associated with higher average age. Conclusions . XML plus conventional treatment demonstrated a significant effect in reducing cardiac dysfunction in HF patients, and age is a potential factor of higher efficacy. Given the heterogeneity and bias of the included RCTs, large, prospective, rigorous trials are still needed.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: